| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Pathology, Timone Hospital, Marseille, France
Breast tissue samples, including normal breast, nonmalignant disorders, and breast carcinomas (n = 257), were tested with monoclonal antibody Ki67 to define the growth fraction in each tissue subgroup. Immunocytochemical assays using anti-Ki67 and avidin-biotin-peroxidase complex and/or alkaline phosphatase anti-alkaline phosphatase were applied in frozen sections. The immunoreactions were analyzed with a computerized system of image analysis referred to as SAMBA (Systeme d'Analyse Microphotometrique à Balayage Automatique). This system permitted a multiparametric and automatized analysis of colored images. The results obtained were: (a) the SAMBA analysis of Ki67-positive staining was accurate, reliable, and reproducible; (b) the anti-Ki67 immunostaining was significantly (P < 0.01) increased in malignancies and was related to the tumors' degree of differentiation, the vascular invasion, and the presence of axillary lymph node metastases; (c) anti-Ki67 immunostaining is increased (P < 0.01) in tumors in which estrogen receptor and progesterone receptor antigenic sites are not detected. It is concluded that the SAMBA analysis of the anti-Ki67 immunocytochemical assay provides relevant information in selecting subgroups of patients with higher risk for relapse.
1 This study was supported partly by grants from the LNLC, the ARC, the GEFLUC, the CR of Marseille and grant from Marseille Medical School.
2 To whom requests for reprints should be addressed, at Laboratoire d'Anatomie Pathologique (Pr. M. Toga), Faculté de Médecine, 27 Bd Jean Moulin 13385, Marseille Cedex 05, France.
Received 12/11/87. Revised 3/29/88. Accepted 4/25/88.
This article has been cited by other articles:
![]() |
S Dubois, S Guyetant, P Menei, P Rodien, F Illouz, B Vielle, and V Rohmer Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery Eur. J. Endocrinol., August 1, 2007; 157(2): 141 - 147. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |